Displaying publications 221 - 240 of 4830 in total

Abstract:
Sort:
  1. Lee YY, Gangireddy V, Khurana S, Rao SS
    Gastroenterology, 2014 Aug;147(2):544.
    PMID: 24976027 DOI: 10.1053/j.gastro.2014.03.053
    Matched MeSH terms: Anti-Inflammatory Agents, Non-Steroidal/therapeutic use*; Antibodies, Monoclonal/therapeutic use*; Azathioprine/therapeutic use*; Immunosuppressive Agents/therapeutic use*
  2. Jothy SL, Oon CE, Sasidharan S
    Asian Pac J Cancer Prev, 2014;15(3):1501.
    PMID: 24606490
    Matched MeSH terms: Antineoplastic Agents/therapeutic use*; Antioxidants/therapeutic use; Oxidants/therapeutic use*; Reactive Oxygen Species/therapeutic use*
  3. Awan KH, Patil S, Habib SR, Pejcic A, Zain RB
    J Contemp Dent Pract, 2014 Nov 1;15(6):812-7.
    PMID: 25825114
    Oral submucous fibrosis is a chronic, progressive scarring disease associated with both significant morbidity including pain and limited mouth opening and an increased risk for malignancy. This systematic review evaluated the different medicinal (i.e. nonsurgical) interventions available for the management of oral submucous fibrosis. An automated literature searches of online databases from January 1960 to December 2013 were performed and only studies with high level of evidence based on the guidelines of the Oxford Centre for evidence-based medicine were selected. Thirteen studies (3 randomized controlled trials and 10 clinical trials/controlled clinical trials) were included and drugs like steroids, hyaluronidase, human placenta extracts, chymotrypsin and collagenase, pentoxifylline, nylidrin hydrochloride, iron and multivitamin supplements including lycopene were used. There is a clear lack of evidence on the available drug treatment for oral submucous fibrosis and further high quality randomized controlled trials are needed to evaluate the different therapeutic agents.
    Matched MeSH terms: Adrenal Cortex Hormones/therapeutic use; Antioxidants/therapeutic use; Enzymes/therapeutic use; Vasodilator Agents/therapeutic use
  4. Zaharan NL, Williams D, Bennett K
    Ir J Med Sci, 2014 Jun;183(2):311-8.
    PMID: 24013870 DOI: 10.1007/s11845-013-1011-1
    BACKGROUND: Over the last decade there have been significant changes in the prescribing of antidiabetic therapies. It is of interest to know about these trends and variations in the Irish population so that future prescribing patterns can be estimated.

    AIMS: To examine the trends in prescribed antidiabetic treatments, including variations across age, gender, socioeconomic status and regions in the Irish population over the last 10 years.

    METHODS: The Irish national pharmacy claims database was used to identify patients ≥ 16 years dispensed antidiabetic agents (oral or insulin) from January 2003 to December 2012 through the two main community drug schemes for diabetes. The rate of prescribing per 1,000 population was calculated. Logistic regression was used to examine variations in prescribing in patients with diabetes.

    RESULTS: There was a significant increase in the prescribing of fast and long-acting insulin analogues with a rapid decline in the prescribing of human insulin (p < 0.0001). Increased prescribing of metformin, incretin modulators and fixed oral combination agents was observed (p < 0.0001). Females and older aged patients were more likely to be prescribed human insulin than other insulins. Metformin was less likely while sulphonylureas were more likely to be prescribed in older than younger aged patients. Socioeconomic differences were observed in increased prescribing of the newer and more expensive antidiabetic agents in the non-means tested scheme. Regional variations were observed in the prescribing of both insulin and oral antidiabetic agents.

    CONCLUSION: There has been an increase over time in the prescribing of both insulin and oral antidiabetic agents in the Irish population with increasing uptake of newer antidiabetic agents. This has implications for projecting future uptake and expenditure of these agents given the rising level of diabetes in the population.

    Matched MeSH terms: Hypoglycemic Agents/therapeutic use*; Insulin/therapeutic use*; Metformin/therapeutic use; Incretins/therapeutic use
  5. Bastion ML, Mohamad MH
    BMJ Case Rep, 2012;2012.
    PMID: 22914237 DOI: 10.1136/bcr-2012-006525
    To describe the rare presentation of sympathetic ophthalmia in a teenage girl with no previous known ocular injury.
    Matched MeSH terms: Anti-Inflammatory Agents/therapeutic use; Immunosuppressive Agents/therapeutic use; Methylprednisolone/therapeutic use; Cyclosporine/therapeutic use
  6. Ooi CP, Yassin Z, Hamid TA
    PMID: 20166099 DOI: 10.1002/14651858.CD007845.pub2
    Background: Momordica charantia is not only a nutritious vegetable, but is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control.

    Objectives: To assess the effects of mormodica charantia for type 2 diabetes mellitus.

    Search strategy: Several electronic databases were searched, among these The Cochrane Library (issue 4, 2009), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to November 2009), combined with handsearches. No language restriction was used.

    Selection criteria: Randomized controlled trials that compared momordica charantia with a placebo or a control intervention with or without pharmacological or non-pharmacological interventions were included.

    Data collection and analysis: Two authors independently extracted the data. Risk of bias of trials was evaluated using the parameters of randomization, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of momordica charantia used in interventions (no similar preparation was tested twice).

    Main results: Three randomised controlled trials with up to three months duration and investigating 350 participants met the inclusion criteria. Risk of bias of these trials (only one study was published as a full peer-reviewed publication) was generally high. Two RCTs compared the effect of preparations from different parts of the momordica charantia plants and placebo on the glycemic control in type 2 diabetes mellitus. There was no statistically significant difference compared to placebo. The effects of preparation from the leaves of the plant and glibenclamide were comparable in the third trial. No serious adverse effects were reported in all the trials. There were no documentations of death from any cause, morbidity, (health-related) quality of life and costs.

    Authors' conclusions: There is insufficient evidence to recommend momordica charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of momordica charantia are needed before RCTs are established to guide any recommendations in clinical practice.
    Matched MeSH terms: Glyburide/therapeutic use; Hypoglycemic Agents/therapeutic use*; Riboflavin/therapeutic use; Plant Preparations/therapeutic use*
  7. Ziganshina LE, Vizel AA, Squire SB
    PMID: 16034951
    Fluoroquinolones are sometimes used to treat multiple-drug-resistant and drug-sensitive tuberculosis. The effects of fluoroquinolones in tuberculosis regimens need to be assessed.
    Matched MeSH terms: Antitubercular Agents/therapeutic use*; Ciprofloxacin/therapeutic use; Ofloxacin/therapeutic use; Fluoroquinolones/therapeutic use*
  8. Shahidah KN, Merican I
    Med J Malaysia, 2005 Jul;60 Suppl B:35-8.
    PMID: 16108171
    Matched MeSH terms: Antiviral Agents/therapeutic use; Drugs, Chinese Herbal/therapeutic use*; Interferon-alpha/therapeutic use; Lamivudine/therapeutic use
  9. Hassan Y, Awaisu A, Aziz NA, Ismail O
    Pharm World Sci, 2005 Feb;27(1):16-9.
    PMID: 15861930
    Phenytoin has been reported to have major interactions with warfarin. Phenytoin induces warfarin's metabolism. However, there are many case reports which provide conflicting conclusions. Here, we report a case of a 65-year-old man with mechanical heart valve on chronic warfarin therapy who experienced persistent fluctuations of INR and bleeding secondary to probable warfarin-phenytoin interactions. The patient's anticoagulation clinic visits prior to hospitalization were thoroughly evaluated and we continued to follow-up the case for 3 months post-hospitalization. The reported interaction could be reasonably explained from the chronology of events and the pattern of INR fluctuations whenever phenytoin was either added or discontinued from his drug regimen.
    Matched MeSH terms: Anticoagulants/therapeutic use; Anticonvulsants/therapeutic use; Phenytoin/therapeutic use; Warfarin/therapeutic use
  10. Hanna L
    BETA, 1999 Apr;12(2):8-9.
    PMID: 11366704
    Matched MeSH terms: Coumarins/therapeutic use*; Plant Extracts/therapeutic use*; Reverse Transcriptase Inhibitors/therapeutic use*; Anti-HIV Agents/therapeutic use*
  11. Fauzi ARM
    Med J Malaysia, 2000 Dec;55(4):529-37; quiz 538.
    PMID: 11221172
    Primary pulmonary hypertension (PPH) is a rare disease. The annual incidence in the West is 1-2 cases per million population per year. A recent WHO symposium in 1998 has produced a consensus on classification, methods of screening, risk assessment and treatment. PPH is a diagnosis of exclusion after all other secondary causes of pulmonary hypertension are ruled out. Current treatment strategy involves acute vasodilator drug trial where positive responders are treated with high dose calcium channel blockers and anticoagulation. Those who do not show positive response may be commenced on intravenous prostacyclin. Surgical treatment is one option for patients with severe PPH or for symptomatic relief. Prognosis in general is very poor.
    Matched MeSH terms: Anticoagulants/therapeutic use; Antihypertensive Agents/therapeutic use; Calcium Channel Blockers/therapeutic use; Epoprostenol/therapeutic use
  12. Badrul B, Ruslan G
    Med J Malaysia, 2000 Sep;55 Suppl C:93-6.
    PMID: 11200051
    We report a 64 year old man who developed Candida albicans infection following total knee arthroplasty. A two-stage exchange arthroplasty was performed after an initial swab culture grew Acinobacter sp. A scanty growth of yeast was also found from the tissue culture. Intravenous cefuroxime was instituted for six weeks followed by reimplantation four months after the removal. Three weeks after that revision, the prosthesis became infected and a culture of knee aspirate established the diagnosis of Candida albicans infection. Treatment consisted of thorough debridement of the involved joint and oral fluconazole for a year. Infection was never totally resolved and a secondary infection with methicillin resistant staphylococcus aureus then developed. Excision arthroplasty was done at two and a half years after the initial infection. At five years follow-up the infection was quiescent and he had a range of movement of 30 degrees to 70 degrees. Knee brace was used to control the valgus-varus stability.
    Matched MeSH terms: Antifungal Agents/therapeutic use; Cefuroxime/therapeutic use; Cephalosporins/therapeutic use; Fluconazole/therapeutic use
  13. Chuah SY
    Med J Malaysia, 1995 Jun;50(2):162-5.
    PMID: 7565187
    Matched MeSH terms: Flumazenil/therapeutic use; Narcotic Antagonists/therapeutic use; Narcotics/therapeutic use; Cholinergic Antagonists/therapeutic use
  14. Goh BL, Morad Z, Cheah PL, Chua CT, Tan SY
    Transplant Proc, 1998 Nov;30(7):3592-3.
    PMID: 9838574
    Matched MeSH terms: Immunosuppressive Agents/therapeutic use*; Tacrolimus/therapeutic use*; Cyclosporine/therapeutic use; Muromonab-CD3/therapeutic use
  15. Black F, Bygbjerg I, Effersøe P, Gomme G, Jepsen S, Jensen GA
    Trans R Soc Trop Med Hyg, 1981;75(5):715-6.
    PMID: 7036431
    A case of Plasmodium falciparum malaria resistant to Fansidar (sulphadoxine plus pyrimethamine) at a level corresponding to R III and resistant to chloroquine is reported. The infection was most certainly acquired in Malaysia, but diagnosed and treated in a non-malarious area. Normal resorption and elimination rates of the Fansidar components excludes cure failure due to abnormal drug fate in the host. P. falciparum parasites from the patient have been maintained in vitro cultures. The patient was permanently cured with mefloquine.
    Matched MeSH terms: Antimalarials/therapeutic use; Pyrimethamine/therapeutic use*; Sulfadoxine/therapeutic use*; Sulfanilamides/therapeutic use*
  16. Sinniah B, Shekhar C, Ramphal L, Senan P
    J R Soc Health, 1984 Jun;104(3):114-5, 118.
    PMID: 6431096
    Matched MeSH terms: Insecticides/therapeutic use*; Malathion/therapeutic use; Pyrethrins/therapeutic use; Carbaryl/therapeutic use
  17. Goh CS
    Med J Malaysia, 1981 Jun;36(2):87-8.
    PMID: 6211594
    Matched MeSH terms: Clindamycin/therapeutic use*; Erythromycin/therapeutic use; Tetracycline/therapeutic use; Tretinoin/therapeutic use*
  18. Mak JW, Navaratnam V, Ramachandran CP
    Ann Trop Med Parasitol, 1991 Feb;85(1):131-7.
    PMID: 1888210
    An intense global collaborative effort under the leadership of the Steering Committee of the Filariasis Scientific Working Group of the Tropical Diseases Research Programme, World Health Organization, has brought together researchers, pharmaceutical chemists and clinicians in the development and search for antifilarial compounds which are more effective and more convenient to administer than diethylcarbamazine citrate, the current drug of choice for lymphatic filariasis. The Brugia spp.-rodent model has been used extensively for the primary screening and B. pahangi infections in the dog or cat for the secondary screening, of potential filaricides. Recently, the leaf-monkey (Presbytis spp.) infected with subperiodic B. malayi or Wuchereria kalimantani has been used for the tertiary evaluation and pharmacokinetic studies of compounds which have shown effectiveness in the primary and secondary screens. Both P. cristata and P. melalophos are extremely susceptible to subperiodic B. malayi infection, but the former is a better host as a higher peak microfilaremia and adult worm recovery rate were obtained. Although more than 30 potential filaricides have been evaluated in the tertiary screen, only a few compounds have shown some promise against lymphatic filariasis. CGP 20376, a 5-methoxyl-6-dithiocarbamic-S-(2-carboxy-ethyl) ester derivative of benzothiazole, had complete adulticidal and microfilaricidal activities against the parasite at a single oral dose of 20 mg kg-1. However, as the compound or its metabolites caused hepatotoxicity, its clinical use in the present formulation is not recommended.(ABSTRACT TRUNCATED AT 250 WORDS)
    Matched MeSH terms: Filaricides/therapeutic use; Ivermectin/therapeutic use; Piperazines/therapeutic use; Thiazoles/therapeutic use
  19. Warrell DA, Looareesuwan S, White NJ, Theakston RD, Warrell MJ, Kosakarn W, et al.
    Br Med J (Clin Res Ed), 1983 Feb 26;286(6366):678-80.
    PMID: 6402200
    Five patients were bitten by the Malayan krait Bungarus candidus (Linnaeus) in eastern Thailand or north western Malaya. Two patients were not envenomed but the other three developed generalised paralysis which progressed to respiratory paralysis in two cases, one of which ended fatally. One patient showed parasympathetic abnormalities. Anticholinesterase produced a dramatic improvement in one patient. Another patient probably benefited from paraspecific antivenom. The efficacy of antivenoms and adjuvants such as anticholinesterases in patients with neurotoxic envenoming requires further study.
    Matched MeSH terms: Antivenins/therapeutic use*; Cholinesterase Inhibitors/therapeutic use*; Edrophonium/therapeutic use; Neostigmine/therapeutic use
  20. Drew R
    Ann Intern Med, 1969 Jan;70(1):147-9.
    PMID: 5763718
    Matched MeSH terms: Proguanil/therapeutic use; Chloroquine/therapeutic use; Pyrimethamine/therapeutic use; Sulfadimethoxine/therapeutic use
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links